NCT03237260 - An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis | Biotech Hunter

Timeline

Start Date

July 1, 2017

Primary Completion Date

February 1, 2019

Study Completion Date

February 1, 2019

Conditions

Ulcerative Colitis

Interventions

DRUG

Vedolizumab

Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg

Trial Locations (2)

Corporal Michael J. Crescenz VA Medical Center, Philadelphia

University of Pennsylvania Medical Center, Philadelphia